Data published on Cesca Therapeutics' technology

The International Journal of the Cardiovascular Academy published data from a pilot study using Cesca Therapeutics Inc.'s (Nasdaq: KOOL) technology to treat acute myocardial infarction. The stock price more than doubled by leaping $2.11 to $4.12.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.